|Day Low/High||78.10 / 79.91|
|52 Wk Low/High||75.77 / 122.00|
And it is happening not a moment too soon.
Dow Theory presents tips for surviving a bear market, some top year-end stock bargains and a simple strategy for monthly income.
SHAK beat expectations for both EPS and revenue, but same-store sales decreased. Here is how I would play it.
Once the safest stocks in the book, the big-cap drug companies are now toxic.
There are no catalysts to drive the stock price higher, so for now, Gilead is simply a cheap stock with a nice dividend.
This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.
This stock is still going wild after earnings.
Markets have perked up just a tad across the board since our last update. As mentioned in an earlier post, Galmed Pharmaceuticals is the second small-cap NASH (nonalcoholic steatohepatitis) play that has soared over the past week. The shares are up ...
Options spreads aren't tradable with some small biotechs, making shares the only way to play.
KLA-Tencor, Microsoft and Intel all report earnings after the close Thursday.
I think M&A activity will pick up markedly going forward across the industry.
These names are displaying signs of either bullish or bearish reversal patterns over the past week.
Markets have improved somewhat in the past 90 minutes. The Dow and S&P 500 are now in the black with other major indices nearing even. Some quick observations about some stocks with less than two hours left to end the week. AbbVie clawing back a tad...
No sector offered respite from Thursday's tariff-inspired selloff.
Traders should still be long and looking for higher highs. Let's check the charts and indicators again.
Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.
There is nothing wrong with Intel, Johnson & Johnson, 3M and Apple.
A roundup of biotech names with actions pending at the FDA in coming weeks.
Don't worry about missing anything, we haven't solved the bond conundrum and the evidence says we get to 3% with selloffs on the way.
I added to two positions Tuesday, as growth catalysts are in play this earnings season.
The biotech sector has seen a big rally, but there are still opportunities.